Introduction:
Over 20% of FDA 483 observations issued to pharmaceutical companies last year were tied to calibration or equipment maintenance failures.
Our new eBook, “Calibration Trends in 2025: What Life Sciences Companies Should Watch For” explores the key calibration trends impacting pharma, biotech, and MedTech companies in 2025, and how to stay ahead.
Inside You’ll Learn:
- Why calibration is now boardroom-level
- Top FDA findings tied to calibration failures
- Risks of missing certificates and poor documentation
- How calibration supports innovation and patient safety
- Actionable steps to reduce compliance risk